Parameter
| Biomarker | CIP2A | Full name | Cancerous Inhibitor of Protein Phosphatase 2A | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, prediction of treatment failure |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Diagnostic sample (protein level detection) | ||
| Pathobiological Mechanisms | Overexpression is associated with disease progression and treatment failure, with this effect observed only in patients treated with dasatinib. | ||||
| Clinical Availability Status | Research validation: Clinical trials have confirmed its association with progression-free survival and treatment failure rate. | ||||
| Notes and Dynamics | It can serve as a simple and feasible diagnostic biomarker, providing a reference for the formulation of therapeutic strategies. | ||||